Improving Outcomes in EGFR-Mutated Non-Small-Cell Lung Cancer: Global Insights on Evolving Practice Standards

In this episode, Enriqueta Felip, MD, PhD, and Matthew Gubens, MD, MS, discuss evolving practice standards for EGFR-mutated non-small-cell lung cancer with topics including:

• Biomarker testing and strategies
• Optimal first-line therapy in patients with NSCLC
• Management of patients with CNS disease
• Selecting therapy for patients with noncanonical mutations
• Management strategies after progression on first-line EGFR TKI therapy
• Selecting therapy for patients with early stage disease

Presenters: 

Enriqueta Felip, MD, PhD
Head, Thoracic Oncology Unit
Oncology Service
Vall d'Hebron University Hospital
Barcelona, Spain

Matthew Gubens, MD, MS
Associate Professor
Thoracic Oncology
University of California, San Francisco
San Francisco, California

Content based on an online CME program supported by an educational grant from AstraZeneca.

Link to full program, including associated downloadable slidesets:
https://bit.ly/2PpFFHM